All In Biotech

Drug Trial Radar · NCT06784752

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

May 30, 2025

Primary completion

Dec 8, 2028

Study completion Jan 23, 2034

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden

Conditions

  • Somatostatin Receptor Positive (SSTR+)
  • Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Interventions

  • [177Lu]Lu-DOTA-TATERadiation

    \[177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)

  • Octreotide LARDrug

    Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W. In the control arm Octreotide LAR will be administered Q4W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC)Time frame: After observing approximately 88 PFS events as per BIRC assessments, expected after approximately 33 months from study start

Locations

67 sites in 12 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Yale New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • Piedmont Healthcare

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • St Elizabeth Healthcare

    Edgewood, Kentucky · Recruiting

  • LSU Medical Center

    New Orleans, Louisiana · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • TxO Austin Midtown

    Austin, Texas · Active not recruiting

  • Texas Oncology

    Dallas, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Blue Ridge Cancer Center

    Wytheville, Virginia · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

  • Novartis Investigative Site

    Edmonton, Alberta, Canada · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Bron, France · Recruiting

  • Novartis Investigative Site

    Clichy, France · Recruiting

  • Novartis Investigative Site

    Montpellier, France · Recruiting

  • Novartis Investigative Site

    Nantes, France · Recruiting

  • Novartis Investigative Site

    Pessac, France · Recruiting

  • Novartis Investigative Site

    Toulouse, France · Recruiting

  • Novartis Investigative Site

    Erlangen, Germany · Recruiting

  • Novartis Investigative Site

    Essen, Germany · Recruiting

  • Novartis Investigative Site

    München, Germany · Recruiting

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Szeged, Hungary · Recruiting

  • Novartis Investigative Site

    Cona, FE, Italy · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.